tert-butyl N-[2-(2-hydroxyethoxy)ethoxy]-N-methylcarbamate | 1023955-77-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl N-[2-(2-hydroxyethoxy)ethoxy]-N-methylcarbamate
• 英文别名: tert-butyl 2-(3-hydroxypropoxy)ethoxy(methyl)carbamate；[2-(2-Hydroxyethoxy)ethoxy]methylcarbamic acid tert-butyl ester
• CAS: 1023955-77-2
• 化学式: C₁₀H₂₁NO₅
• 分子量: 235.28
• InChiKey: DMFUUJSWBPEOGL-UHFFFAOYSA-N

物化性质

• 沸点：
  331.3±22.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  68.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[2-(2-hydroxyethoxy)ethoxy]-N-methylcarbamate 在 戴斯-马丁氧化剂 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl N-methyl-N-[2-(2-oxoethoxy)ethoxy]carbamate
  参考文献：
  名称：

  [EN] HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE
  [FR] COMPOSÉS HÉTÉROBIFONCTIONNELS ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES

  摘要：

  The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC which is linked to a moiety that binds to a target protein selected from BTK, androgen receptor or IDH1. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.

  公开号：

  WO2023059583A1
• 作为产物：
  描述：

  N-羟基-N-甲基氨基甲酸叔丁酯 、 2-氯乙氧基乙醇 在 potassium carbonate 、 lithium bromide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以72%的产率得到tert-butyl N-[2-(2-hydroxyethoxy)ethoxy]-N-methylcarbamate
  参考文献：
  名称：

  [EN] ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES
  [FR] AUGMENTATION DE L'IMMUNOGÉNICITÉ DES ANTIGÈNES ASSOCIÉS AUX TUMEURS PAR L'ADJONCTION D'ÉPITOPES aGAL

  摘要：

  公开号：

  WO2008057235A3

文献信息

• Site‐specific addition of an ¹⁸F‐<i>N</i>‐methylaminooxy‐containing prosthetic group to a vinylsulfone modified peptide
  作者：Dag Erlend Olberg、Ole Kristian Hjelstuen、Magne Solbakken、Joseph M. Arukwe、Knut Dyrstad、Alan Cuthbertson

  DOI：10.1002/jlcr.1686

  日期：2009.12

  Numerous strategies employing prosthetic groups for the radiosynthesis of ¹⁸F‐fluorinated peptides for positron emission tomography have been investigated in recent years. We have previously reported a novel [¹⁸F]prosthetic group bearing the N‐methylaminooxy functionality capable of reacting in a site‐selective manner with peptides functionalized with Michael‐acceptors. In a further extension of this methodology we demonstrate that O‐[2‐(2‐[¹⁸F]fluoroethoxy)ethyl]‐N‐methyl‐N‐hydroxylamine, [¹⁸F]4, reacts chemoselectively with a vinylsulfone functionalized peptide. The conjugation yields were studied with respect to reaction time, level of radioactivity, peptide concentration and purity of the [¹⁸F]prosthetic group used in the conjugation reaction. Incubation at 70°C gave conjugation yields of around 80% with high radiochemical purity after 70 min at pH 5 in acetate buffer. Copyright © 2009 John Wiley & Sons, Ltd.

  摘要 近年来，人们研究了许多利用人工基团进行放射合成正电子发射断层扫描用 18F 含氟肽的策略。我们以前曾报道过一种新型的[18F]修复基团，它具有 N-甲基氨基氧基官能团，能够以位点选择性的方式与迈克尔受体官能化的肽发生反应。在这一方法的进一步扩展中，我们证明了 O-[2-（2-[18F]氟乙氧基）乙基]-N-甲基-N-羟胺（[18F]4）与乙烯砜官能化肽的化学选择性反应。研究了共轭产率与反应时间、放射性水平、肽浓度和共轭反应中使用的[18F]修复基团纯度的关系。在醋酸盐缓冲液中的 pH 值为 5 时，70°C 下孵育 70 分钟后，共轭产率约为 80%，放射化学纯度很高。Copyright © 2009 John Wiley & Sons, Ltd. All Rights Reserved.
• RADIOFLUORINATION METHODS
  申请人：Cuthbertson Alan

  公开号：US20100196270A1

  公开（公告）日：2010-08-05

  The invention relates to conjugates of formula (V) or (VI), their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.

  本发明涉及公式（V）或（VI）的共轭物，它们作为放射性药物的用途，用于它们的制备过程以及用于这种过程中的合成中间体。
• ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES
  申请人：MAUTINO Mario R.

  公开号：US20120003251A1

  公开（公告）日：2012-01-05

  The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

  本发明涉及用于选择性靶向和杀死肿瘤细胞的方法和组合物。本发明描述了基于纯化的TAA蛋白或经化学、酶或化酶改变的TAA衍生合成肽的预防性或治疗性癌症疫苗，以引入αGal表位或αGal糖类模拟表位，从而通过天然抗-αGal抗体增强抗原的包被作用，促进TAA的捕获和呈递，从而诱导对肿瘤细胞表达的TAA的体液和细胞免疫反应。动物的免疫系统因此被刺激产生特异性的肿瘤细胞毒性细胞和抗体，这些细胞和抗体将攻击和杀死动物体内存在的肿瘤细胞。
• Radiofluorination methods
  申请人：Cuthbertson Alan

  公开号：US08444955B2

  公开（公告）日：2013-05-21

  The invention relates to conjugates of formula (V) or (VI), their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.

  本发明涉及公式（V）或（VI）的共轭物，它们的用途作为放射性药物，用于它们的制备过程以及用于这种过程的合成中间体。
• US8444955B2
  申请人：——

  公开号：US8444955B2

  公开（公告）日：2013-05-21